DK1484404T3 - Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner - Google Patents

Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner

Info

Publication number
DK1484404T3
DK1484404T3 DK04076971T DK04076971T DK1484404T3 DK 1484404 T3 DK1484404 T3 DK 1484404T3 DK 04076971 T DK04076971 T DK 04076971T DK 04076971 T DK04076971 T DK 04076971T DK 1484404 T3 DK1484404 T3 DK 1484404T3
Authority
DK
Denmark
Prior art keywords
val
tyr
preparation
toxin
ser
Prior art date
Application number
DK04076971T
Other languages
Danish (da)
English (en)
Inventor
Mario Domenighini
Rino Rappuoli
Mariagrazia Pizza
Wim Hol
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11361457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1484404(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1484404T3 publication Critical patent/DK1484404T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04076971T 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner DK1484404T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI913513A IT1253009B (it) 1991-12-31 1991-12-31 Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
PCT/EP1992/003016 WO1993013202A1 (fr) 1991-12-31 1992-12-30 Mutants immunogenes detoxiques de la toxine du cholera et des toxines thermolabiles (lt), preparation et utilisation de ces mutant pour la preparation de vaccins

Publications (1)

Publication Number Publication Date
DK1484404T3 true DK1484404T3 (da) 2007-03-19

Family

ID=11361457

Family Applications (3)

Application Number Title Priority Date Filing Date
DK98200534T DK0869181T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af LT-tolsin, fremstillingen deraf og anvendelsen deraf til fremstilling af vacciner
DK04076971T DK1484404T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner
DK93902138T DK0620850T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, deres fremstilling og deres anvendelse til fremstil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98200534T DK0869181T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af LT-tolsin, fremstillingen deraf og anvendelsen deraf til fremstilling af vacciner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK93902138T DK0620850T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, deres fremstilling og deres anvendelse til fremstil

Country Status (18)

Country Link
US (1) US6149919A (fr)
EP (3) EP1484404B1 (fr)
JP (2) JP3394774B2 (fr)
AT (3) ATE277183T1 (fr)
AU (1) AU3347693A (fr)
CA (1) CA2127091C (fr)
DE (3) DE69233667T2 (fr)
DK (3) DK0869181T3 (fr)
ES (3) ES2277195T3 (fr)
GR (1) GR3029556T3 (fr)
IT (1) IT1253009B (fr)
MX (1) MX9207685A (fr)
MY (1) MY108154A (fr)
PT (1) PT1484404E (fr)
SA (1) SA93130462B1 (fr)
SG (2) SG48217A1 (fr)
TW (1) TW239146B (fr)
WO (1) WO1993013202A1 (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
DK0725653T3 (da) 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US5981730A (en) * 1994-04-13 1999-11-09 The General Hospital Corporation RPS gene family, primers, probes, and detection methods
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6436407B1 (en) 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
GB9603314D0 (en) * 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
AU6044598A (en) * 1997-01-29 1998-08-18 The Administrators Of The Tulane Eductional Fund Mutant enterotoxin effective as a non-toxic adjuvant for hiv
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1486215A3 (fr) * 1997-03-21 2006-04-12 Chiron Corporation Mutants détoxifies de toxines bactériennes ribolysant l'ADP utilisés comme adjuvants parentéraux
EP0887403A3 (fr) * 1997-06-27 2000-12-06 Chiron S.P.A. Souches atténuées de Vibrio cholerae
AU9120898A (en) 1997-08-27 1999-03-16 Chiron Corporation Molecular mimetics of meningococcal b epitopes
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
AU3089599A (en) * 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
AU770498B2 (en) 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
DE19851282A1 (de) * 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
EP1175144A4 (fr) * 1998-12-22 2002-10-30 Thompson Boyce Plant Res Enterotoxines bacteriennes immunogenes a administration par voie orale, exprimees dans des plantes transgeniques
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (fr) 1998-12-31 2013-05-07 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
AU4673099A (en) 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US7722887B1 (en) * 1999-09-15 2010-05-25 Mogam Biotechnology Research Institute Detoxified mutants of escherichia coli heat-labile enterotoxin
US7186560B2 (en) * 1999-09-21 2007-03-06 Rutgers, The State University Of New Jersey High level expression of immunogenic proteins in the plastids of higher plants
ES2296642T3 (es) * 1999-09-21 2008-05-01 Rutgers, The State University Of New Jersey Sistema de recombinacion especifica de sitio para manipular el genoma de plastidos de plantas superiores.
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU2471201A (en) 1999-10-26 2001-06-06 Chiron Corporation Plant lectins as mucosal adjuvants
US20020142006A1 (en) * 2000-03-17 2002-10-03 Mcghee Jerry R. Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
US7063852B2 (en) 2000-05-19 2006-06-20 The Administrators Of The Tulane Educational Fund Hybrid LT-A/CT-B holotoxin for use as an adjuvant
EP2336368A1 (fr) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène à régulation positive dans le cancer de la prostate
DE60239317D1 (de) 2001-01-12 2011-04-14 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
WO2002074244A2 (fr) 2001-03-19 2002-09-26 Iomai Corporation Immunostimulation transcutanee
AU2002252525A1 (en) * 2001-03-29 2002-10-15 Rutgers, The University Of New Jersey Integrases for the insertion of heterologous nucleic acids into the plastid genome
CA3060687C (fr) 2001-05-22 2021-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mise au point de mutations utiles pour l'attenuation des virus de la dengue et des virus de la dengue chimeriques
EP1404368B1 (fr) * 2001-06-07 2009-12-09 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera en tant qu'adjuvant
KR20080078717A (ko) 2001-06-07 2008-08-27 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP2280074A3 (fr) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
MXPA04000653A (es) 2001-07-27 2004-11-22 Chiron Srl Adhesinas de meningococcus nada, app y orf 40.
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2476626A1 (fr) 2002-02-20 2003-08-28 Chiron Corporation Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
MXPA04008890A (es) 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
AU2003274925A1 (en) * 2002-08-27 2004-03-19 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
US20080159957A1 (en) 2002-10-01 2008-07-03 W Michael Kavanaugh Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
DK2395073T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying.
EP1581256A4 (fr) * 2002-11-14 2006-06-07 Pfizer Prod Inc Utilisation de rmlt en tant qu'antigene marqueur pour vaccins et en tant qu'adjuvant synergetique avec amphigen
EP2263687B1 (fr) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes contenant des phospholipides
US6743002B1 (en) * 2003-02-03 2004-06-01 Eaton Corporation Rotary fluid pressure device and improved integral brake assembly
AU2003274904A1 (en) * 2003-02-14 2004-09-09 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
EP1606386A4 (fr) * 2003-03-03 2007-07-18 Univ Rutgers Elimination de sequences de plastides a l'aide de recombinases specifiques de sites, a expression transitoire
EP1603950A2 (fr) * 2003-03-17 2005-12-14 Wyeth Holdings Corporation Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0313242D0 (en) * 2003-06-09 2003-07-16 Imp College Innovations Ltd Pulmonary immunopathology
WO2005021033A2 (fr) 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccin
EP1814583A2 (fr) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Approches combinatoires destinées à produire des réponses immunitaires
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
EP2425855A1 (fr) 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
WO2007047749A1 (fr) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus
WO2007121467A2 (fr) * 2006-04-18 2007-10-25 Rutgers, The State University Of New Jersey Compositions et procédés destinés à augmenter l'expression de transgènes dans les plastes des plantes supérieures
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008094188A2 (fr) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Procédés et compositions utilisant la listeria pour renforcer l'immunogénicité par primo-immunisation
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
EP2268297A4 (fr) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Toxines modifiées
EP2293813A4 (fr) 2008-05-23 2012-07-11 Univ Michigan Vaccins à nanoémulsion
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010046783A2 (fr) * 2008-10-21 2010-04-29 International Vaccine Institute Fragment a1 de sous-unité a de toxine du choléra utilisé en tant qu'adjuvant pour des vaccins mucosaux et systémiques
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
EP2405758B1 (fr) 2009-03-09 2016-04-27 Molecular Express, Inc. Procédés et compositions pour formulation liposomale d'antigènes et leurs utilisations
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
RU2531234C2 (ru) 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
US8241608B2 (en) 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
CN102947452A (zh) 2010-05-23 2013-02-27 艾杜罗生物科技公司 使用用于癌症的辅佐治疗的李斯特菌属的方法和组合物
PL2575870T3 (pl) 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
SI3246044T2 (sl) 2010-08-23 2024-06-28 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EP2654784B1 (fr) 2010-12-22 2016-12-07 Wyeth LLC Compositions immunogènes stables d'antigènes de staphylococcus aureus
KR101998431B1 (ko) 2011-04-26 2019-07-09 몰레큘라 익스프레스 인코포레이티드 리포솜 제제
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
AU2012340035A1 (en) 2011-11-14 2014-04-17 Susan W. Barnett Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
WO2014044690A1 (fr) 2012-09-18 2014-03-27 Valneva Austria Gmbh Vaccins améliorés
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
EP4169929A1 (fr) 2012-12-20 2023-04-26 Pfizer Inc. Compositions immunogènes comprenant le pn- serotype 12f
EP2950819B1 (fr) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
EP3041502A2 (fr) 2013-09-08 2016-07-13 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procédés associés
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
CA2929126C (fr) 2013-11-13 2020-01-07 University Of Oslo Vesicules de membrane externe et utilisation associees
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2016130569A1 (fr) 2015-02-09 2016-08-18 Mj Biologics, Inc. Composition contenant des antigènes du vdep et procédés de fabrication et d'utilisation de la composition
WO2015138455A1 (fr) 2014-03-11 2015-09-17 Regents Of The University Of Minnesota Vaccins contre le virus de la diarrhée épidémique porcine et procédés d'utilisation de ceux-ci
WO2016057921A1 (fr) 2014-10-10 2016-04-14 Baker Jr James R Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
WO2016141320A2 (fr) 2015-03-05 2016-09-09 Northwestern University Virus non neuro-invasifs et leurs utilisations
WO2016179034A2 (fr) 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Procédés et compositions permettant de stimuler une réponse immunitaire à l'aide de motifs d'arn immunostimulateurs puissants
IL297740A (en) 2015-05-04 2022-12-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
WO2017040387A2 (fr) 2015-08-31 2017-03-09 Technovax, Inc. Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
CR20180445A (es) 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
WO2017210215A1 (fr) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Vaccin contre le virus zika et procédés d'utilisation
EP3471761A2 (fr) 2016-06-21 2019-04-24 University Of Oslo Fragments de vaccin de liaison à hla et leurs utilisations
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
US10525119B2 (en) 2017-03-31 2020-01-07 Boston Medical Center Corporation Methods and compositions using highly conserved pneumococcal surface proteins
WO2019048936A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules vaccinales
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
WO2021211279A1 (fr) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota Domaine de liaison au récepteur de spicule du sars-cov-2 et compositions et méthodes associées
CA3192786A1 (fr) 2020-08-26 2022-03-03 Pfizer Inc. Conjugues polysaccharide-proteine de streptococcus du groupe b, procedes de production de conjugues, compositions immunogenes comprenant les conjugues et leurs utilisations
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
CN113788893B (zh) * 2021-08-11 2022-08-09 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种快速富集霍乱弧菌的偶联特异性单克隆抗体的免疫磁珠及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8333131D0 (en) * 1983-12-12 1984-01-18 Glaxo Group Ltd Microbiological process
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs

Also Published As

Publication number Publication date
DE69233417T2 (de) 2005-09-29
EP0620850A1 (fr) 1994-10-26
JP3408529B2 (ja) 2003-05-19
DK0620850T3 (da) 1999-09-27
ES2227762T3 (es) 2005-04-01
ES2277195T3 (es) 2007-07-01
ES2127808T3 (es) 1999-05-01
ITMI913513A1 (it) 1993-07-01
JP3394774B2 (ja) 2003-04-07
MX9207685A (es) 1994-05-31
SG48217A1 (en) 1998-04-17
DE69228563T2 (de) 1999-07-29
DE69233667D1 (de) 2007-01-11
CA2127091A1 (fr) 1993-07-08
DE69233417D1 (de) 2004-10-28
IT1253009B (it) 1995-07-10
ATE277183T1 (de) 2004-10-15
ATE346932T1 (de) 2006-12-15
PT1484404E (pt) 2007-03-30
SG93200A1 (en) 2002-12-17
CA2127091C (fr) 2000-08-01
SA93130462B1 (ar) 2004-09-01
EP1484404A1 (fr) 2004-12-08
TW239146B (fr) 1995-01-21
JP2003000287A (ja) 2003-01-07
ITMI913513A0 (it) 1991-12-31
JPH07506240A (ja) 1995-07-13
DE69233667T2 (de) 2007-09-27
WO1993013202A1 (fr) 1993-07-08
MY108154A (en) 1996-08-30
DE69228563D1 (de) 1999-04-08
EP0620850B1 (fr) 1999-03-03
EP0869181A1 (fr) 1998-10-07
GR3029556T3 (en) 1999-06-30
DK0869181T3 (da) 2005-01-31
ATE177145T1 (de) 1999-03-15
EP0869181B1 (fr) 2004-09-22
EP1484404B1 (fr) 2006-11-29
AU3347693A (en) 1993-07-28
US6149919A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
DK1484404T3 (da) Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner
DE69636735D1 (de) Immunogene, ungiftige choleratoxinmutante
DE69734110D1 (de) Immunogene, nichtgiftige mutante des toxins lt-a aus e.coli
US8318148B2 (en) Attenuated bacteria useful in vaccines
JPH06206900A (ja) 融合タンパク質
DK0703981T3 (da) Immunogene sammensætninger mod Helicobacterinfektion, polypeptider til anvendelse i sammensætningerne og nucleinsyresekvenser, som koder for nævnte polypeptider
Magagnoli et al. Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin
AU2002321652A1 (en) Attenuated bacteria useful in vaccines
JP4599354B2 (ja) 大腸菌熱不安定性エンテロトキシンサブユニットに融合した志賀毒素サブユニットまたは志賀毒素様毒素サブユニットを含むハイブリッド毒素およびそのワクチン
FI891832A0 (fi) Specialmutant av escherichia coli.
EP0368819A1 (fr) Expression de la sous-unité liante de la toxine chloérique à l'aide de promoteurs étrangers et/ou de séquences guides
IT1190884B (it) Composizione di un immunogeno per la protezione contro la diarrea provocata da escherichia coli enterotossinogena